MEK INHIBITOR TRAMETINIB IN HIGH GRADE OVARIAN CANCER PROLIFERATION

被引：0
|
作者：
Chesnokov, Mikhail [1 ]
Jamroze, Anmbreen [1 ]
Ha, Wootae [1 ]
Chefetz, Ilana [1 ]
机构：
[1] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA
来源：
CLINICAL CANCER RESEARCH | 2019年 / 25卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
GMM-019
引用
收藏
页码：82 / 82
页数：1
相关论文
共 50 条
  • [41] High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma
    Hollis, Robert L.
    Elliott, Richard
    Dawson, John C.
    Ilenkovan, Narthana
    Matthews, Rosie M.
    Stillie, Lorna J.
    Oswald, Ailsa J.
    Kim, Hannah
    Fernandez, Marta Llaurado
    Churchman, Michael
    Porter, Joanna M.
    Roxburgh, Patricia
    Unciti-Broceta, Asier
    Gershenson, David M.
    Herrington, C. Simon
    Carey, Mark S.
    Carragher, Neil O.
    Gourley, Charlie
    GYNECOLOGIC ONCOLOGY, 2024, 186 : 42 - 52
  • [42] The MEK Inhibitor Trametinib Selectively Suppresses GVHD, While Sparing GVT Effects
    Itamura, Hidekazu
    Shindo, Takero
    Tawara, Isao
    Kariya, Ryusho
    Okada, Seiji
    Komanduri, Krishna V.
    Kimura, Shinya
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) : S333 - S334
  • [43] Partial Remission of a multisystemic Langerhans Cell Histiocytosis by the Usgae of the Trametinib MEK Inhibitor
    Papapanagiotou, M.
    Hillen, U.
    Roesch, A.
    Leyh, J.
    Meyenburg, S.
    Sucker, A.
    Schadendorf, D.
    Livingstone, E.
    Schilling, B.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 43 - 43
  • [44] Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers
    Dai, Xinyu
    Xia, Hongwei
    Zhou, Sheng
    Tang, Qiulin
    Bi, Feng
    CANCER LETTERS, 2019, 442 : 202 - 212
  • [45] The MEK Inhibitor Trametinib Improves Outcomes following Subarachnoid Haemorrhage in Female Rats
    Bomers, Jesper Peter
    Grell, Anne-Sofie
    Edvinsson, Lars
    Johansson, Sara Ellinor
    Haanes, Kristian Agmund
    PHARMACEUTICALS, 2022, 15 (12)
  • [46] High-grade ovarian cancer associated H/ACA snoRNAs promote cancer cell proliferation and survival
    Faucher-Giguere, Laurence
    Roy, Audrey
    Deschamps-Francoeur, Gabrielle
    Couture, Sonia
    Nottingham, Ryan M.
    Lambowitz, Alan M.
    Scott, Michelle S.
    Abou Elela, Sherif
    NAR CANCER, 2022, 4 (01):
  • [47] The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
    Rachna T Shroff
    Mark Yarchoan
    Ashley O'Connor
    Denise Gallagher
    Marianna L Zahurak
    Gary Rosner
    Chimela Ohaji
    Susan Sartorius-Mergenthaler
    Vivek Subbiah
    Ralph Zinner
    Nilofer S Azad
    British Journal of Cancer, 2017, 116 : 1402 - 1407
  • [48] Targeting RAS-ERK pathway alterations with MEK inhibitors to improve chemosensitivity in high grade serous ovarian cancer
    Nguyen, Nancy
    Brooks, Rebecca
    Leiserowitz, Gary
    Chien, Jeremy
    GYNECOLOGIC ONCOLOGY, 2022, 164 (01) : E3 - E4
  • [49] Prexasertib: an investigational checkpoint kinase inhibitor for the treatment of high-grade serous ovarian cancer
    Evangelisti, Giulio
    Barra, Fabio
    Moioli, Melita
    Sala, Paolo
    Stigliani, Sara
    Gustavino, Claudio
    Costantini, Sergio
    Ferrero, Simone
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (08) : 779 - 792
  • [50] Aromatase inhibitor maintenance therapy in high grade advanced ovarian cancer to delay first recurrence
    Knipprath-Meszaros, Alexandra Maria
    Vetter, Marcus
    Montavon, Celine
    Vigo, Francesco
    Schoetzau, Andreas
    Heinzelmann-Schwarz, Viola A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345